Advertisements


GlaxoSmithKline And Merck KGaA Position For The Next Wave In Immuno-Oncology

GlaxoSmithKline And Merck KGaA Position For The Next Wave In Immuno-Oncology.....»»

Category: topSource: seekingalphaFeb 11th, 2019

Merck upgraded to Overweight on immuno-oncology leadership at Morgan Stanley

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 17th, 2018

BioLineRx expands immuno-oncology collaboration with Merck

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 30th, 2018

Merck, Bristol-Myers profits rise on cancer drug sales

Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments......»»

Category: topSource: reutersOct 25th, 2018

Merck KGaA could receive up to about $4.2 bln in milestone payments as part of GlaxoSmithKline deal

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchFeb 5th, 2019

Merck KGaA to receive upfront payment of about $342.8 mln as part of GlaxoSmithKline collaboration

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchFeb 5th, 2019

GlaxoSmithKline, Merck KGaA to collaborate on cancer treatments

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchFeb 5th, 2019

GlaxoSmithKline and Merck KGaA to strike immunotherapy deal worth up to $4.23 billion

U.K.-based GlaxoSmithKline plc a.....»»

Category: topSource: marketwatchFeb 5th, 2019

GlaxoSmithKline and Merck KGaA strike immunotherapy deal worth up to $4 billion

U.K.-based GlaxoSmithKline Plc  and Germany-based Merck KGaA are entering a partnership to develop and commercialize a therapy for patients with advanced non-small cell lung cancer in a deal worth up to $4.23 billion, the companies announced Tuesday......»»

Category: topSource: marketwatchFeb 5th, 2019

GSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy......»»

Category: topSource: reutersFeb 5th, 2019

Former FreightWaves Exec Talks Transparency, "Third-Wave" Freight-Tech And The Value Of Empathy

Jenny Xu, former chief strategy officer at FreightWaves, has taken a position as chief executive of Carggo, a digital freight platform that serves small- and medium-size third-party logistics companies. read more.....»»

Category: blogSource: benzinga15 hr. 47 min. ago

Intermolecular stockholders approve acquisition by Merck KGaA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 17th, 2019

Agenus: Out Of Favor Immuno-Oncology Pioneer Powers On

Agenus: Out Of Favor Immuno-Oncology Pioneer Powers On.....»»

Category: topSource: seekingalphaJul 11th, 2019

Roche"s Tecentriq Gets CHMP Recommendation for Breast Cancer

Roche (RHHBY) announced that its immuno-oncology drug, Tecentriq, was recommended for approval by.....»»

Category: worldSource: nytJul 1st, 2019

Merck KGaA downgraded to Underperform from Neutral at BofA/Merrill

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 28th, 2019

Gilead Inks Deal With Carna Biosciences for Immuno-Oncology

Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small mol.....»»

Category: worldSource: nytJun 26th, 2019

The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership

The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership.....»»

Category: earningsSource: benzingaJun 25th, 2019

Versum shareholders approve $5.78B acquisition by German company

As expected, Tempe’s Versum Materials Inc. shareholders on June 17 approved the company's acquisition by Merck KGaA for $53 per share in cash. The buyout deal values Versum at $5.78 billion. Shares of Versum closed Monday at $51.42. The special .....»»

Category: topSource: bizjournalsJun 17th, 2019

Versum Materials shareholders approve merger with Merck KGaA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 17th, 2019

Hemispherx CEO says company has "steady, consistent" progress in immuno-oncology

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 17th, 2019

Merck KGaA"s (MRK) Management Presents at R&D Update Conference - Transcript

Merck KGaA"s (MRK) Management Presents at R&D Update Conference - Transcript.....»»

Category: topSource: seekingalphaJun 14th, 2019